UNICEF Procurement for COVID-19 Vaccines

Etleva Kadilli
UNICEF Supply Division
4 November 2020
DCVMN Annual General Meeting
Impact of COVID-19 on Immunization Programmes

- Disruption of supply chains
- Vaccine shipment disruptions, backlogs, increased costs and delivery complexities
- Disruptions to immunization services, campaigns, outreach services
- Drop in coverage rates
- Increased complexity of forecasting and planning
Weekly Vaccine Shipments: gradually recovered following a dramatic disruption
COVID-19 vaccine introduction trajectory sharply different from other vaccines

Rate of introduction of previous vaccines over time
(Hep B, Hib, PCV, IPV, etc.)

NUMBER OF COUNTRIES

SOURCE: WHO
COVAX Procurement: Key Milestones

**September 2020**
COVAX industry consultation, jointly convened by UNICEF, PAHO and Gavi

**August 2020**
Appointment of UNICEF to lead COVAX procurement for the 92 AMC countries, in collaboration with PAHO, as well as Procurement Coordinator for self-financing countries

**June-July 2020**
Expression of Interest (EOI) to understand manufacturing plans; market assessment developed

**April - June 2020**
Design of the COVAX Facility and AMC

**Iterative**
SAGE Policy recommendations on the use of COVID-19 vaccines once authorized

**January 2021**
Dry run of allocation process

**October - November 2020**
Pooled tender for COVID-19 vaccines issued jointly by UNICEF and PAHO

**January - June 2021**
Allocation and shipments
COVAX demand update

Initial target of COVAX is to deliver at least 2 billion doses of Covid-19 vaccine by the end of 2021

- **92 AMC economies** (estimated 950 million doses, with potential additional doses subject to funding and financing initiatives)
- At least 90 self-financing economies (estimated range from 550-950 million doses)
- Buffer for humanitarian use (100 million doses)

*preliminary split*

As country participation in the COVAX Facility is firmed up, demand forecasts will continue to be refined and estimates adjusted accordingly.
Joint UNICEF/PAHO Procurement of COVID-19 Vaccines

Purpose

• Establish Advance Purchase Commitments (APCs)
• Establish Procurement and Supply Agreements based on APCs
• UNICEF, as COVAX Procurement Coordinator, establishes key basic terms that COVAX self-financing self-procuring participants reference in their supply agreements with manufacturers.

Procurement will be implemented by rolling tender with awards being made in phases:

**Phase 1:**
2 weeks from issuance of RFP:
Manufacturers with an APA (expected to be 1-2 manufacturers)

**Phase 2:**
4 weeks from issuance of RFP:
Manufacturers with doses for delivery in first half of 2021

**Phase 3:**
6 weeks from issuance of RFP:
Manufacturers with doses for delivery in second half of 2021
UNICEF/PAHO Pooled Procurement

Objectives

**Speed**
- Expedite access to Covid-19 vaccines by building on push and pull contracts (established by BMGF, CEPI and Gavi) for the COVAX participating economies

**Volumes**
- ACT-A target is to secure at least 2bn doses by end 2021

**Price**
- Drawing on the financing and de-risking provided by the push and pull contracts and the pooled COVAX volumes, COVAX targets to achieve the lowest prices on the market

**Balanced Portfolio**
- Balanced, geographically diverse portfolio across multiple vaccine platforms

UNICEF as Procurement Coordinator for COVAX Facility

**Monitor supply and demand** based on allocation decisions and prioritisation and in line with the terms of the APCs

**Monitor usage / draw down** of Advance Purchase Agreements

Provide support to and alignment between COVAX procurers on **Terms & Conditions** and supporting consistency towards manufacturers
Country readiness efforts are underway

<table>
<thead>
<tr>
<th>Country Readiness &amp; Delivery Workstream</th>
<th>Key activities for the upcoming months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coordination</td>
<td>Using the <strong>Country Readiness Assessment tool</strong> to plan for COVID-19 vaccine introduction</td>
</tr>
<tr>
<td>Communications, advocacy &amp; training</td>
<td>Preparing for vaccine introduction (i.e. develop National Deployment and Vaccination Plan)</td>
</tr>
<tr>
<td>Data &amp; monitoring</td>
<td></td>
</tr>
<tr>
<td>Delivery cost</td>
<td></td>
</tr>
<tr>
<td>Vaccine introduction</td>
<td></td>
</tr>
<tr>
<td>Demand</td>
<td></td>
</tr>
<tr>
<td>Supply &amp; Logistics</td>
<td></td>
</tr>
</tbody>
</table>

What takes place at country level:

A

What the Country Readiness & Delivery Workstream does:

B

Note: Current expectation of vaccine availability and delivery timelines

- Using the **Country Readiness Assessment tool** to plan for COVID-19 vaccine introduction
- Preparing for vaccine introduction (i.e. develop National Deployment and Vaccination Plan)
- Develop **tools, guidance and SOPs** to support countries getting ready for implementation
- Secure access to products and manage procurement and delivery to countries
- Mobilize resources to support country readiness through targeted technical assistance and Cold Chain Investments
Implementing the COVID-19 Vaccine Introduction Readiness Assessment Tool will require timely planning and action from countries

<table>
<thead>
<tr>
<th>Objectives</th>
<th>CONTENT OF THE CHECKLIST</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WHO &amp; UNICEF Vaccine Introduction Readiness Assessment Tool (VIRAT)</strong></td>
<td><strong>A. Planning &amp; Coordination</strong></td>
</tr>
<tr>
<td>• Provide a planning roadmap to signal what coordination and management mechanisms need to be established to adequately prepare for COVID19 vaccine introduction</td>
<td>Develop the working groups and coordinating bodies that will ensure understanding and adherence to delivery timelines</td>
</tr>
<tr>
<td>• Support countries to self-monitor their readiness progress against key milestones</td>
<td><strong>B. Resources &amp; Funding</strong></td>
</tr>
<tr>
<td></td>
<td>Estimate human and operational resource needs; identify potential sources of funding, and mechanisms for disbursement to operational levels</td>
</tr>
<tr>
<td></td>
<td><strong>C. Regulatory</strong></td>
</tr>
<tr>
<td></td>
<td>Confirm the regulatory pathway for licensing COVID-19 vaccine in country, and secure necessary approvals/waivers for import</td>
</tr>
<tr>
<td></td>
<td><strong>D. Service Delivery</strong></td>
</tr>
<tr>
<td></td>
<td>Establish the priority target populations and develop strategies (traditional or non-traditional) to best reach them</td>
</tr>
<tr>
<td></td>
<td><strong>E. Training &amp; Supervision</strong></td>
</tr>
<tr>
<td></td>
<td>Identify training needs, develop materials / platforms, and deploy to target groups; establish supervision model</td>
</tr>
<tr>
<td></td>
<td><strong>F. Surveillance &amp; Monitoring</strong></td>
</tr>
<tr>
<td></td>
<td>Develop or adapt surveillance mechanisms (coverage, AEFI) for COVID-19, updating data collection tools as needed</td>
</tr>
<tr>
<td></td>
<td><strong>G. Vaccine Logistics &amp; Cold Chain</strong></td>
</tr>
<tr>
<td></td>
<td>Assess and plan for logistics needs (e.g. cold chain, distribution, security) from port of entry through to service delivery points</td>
</tr>
<tr>
<td></td>
<td><strong>H. Safety &amp; Surveillance</strong></td>
</tr>
<tr>
<td></td>
<td>Ensure that sufficient capacity for vaccine safety surveillance is in place</td>
</tr>
<tr>
<td></td>
<td><strong>I. Advocacy, Mobilization &amp; Comms.</strong></td>
</tr>
<tr>
<td></td>
<td>Design and implement communications, social mobilization and engagement strategies to generate confidence, trust and demand for COVID-19 vaccine</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Target countries &amp; points of contact</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>• All 194 WHO Member States</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Country’s EPI Program Manager</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Timeline</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Tool shared with all regional and country offices 3 weeks ago</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Countries expected to provide information on a rolling basis, to be uploaded in Global Immunization Dashboard for global and regional monitoring</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Workstream is working in close connection with the regions, to support country readiness

Roles

**Global level**
- Ensure global public goods are available
- Support regions in adopting global public goods to local context
- Coordinate with COVAX and HSS Connector working groups
- Manage global readiness dashboard to inform allocation and monitor implementation
- Establish global rosters & LTAs for TA an roll-out

**Regional level**
- Regional COVID-19 vaccine working groups manage implementation and leverage existing working modalities, e.g. RITAG and regional working groups
- Coordinate support and provide TA to countries
- Manage regional dashboards on country readiness and implementation progress
- Provide input / review global public goods
- Provide feedback to global level on global progress and bottlenecks

**National level**
- Country COVID-19 vaccine working groups manage implementation of NVDP
- Country working groups support key stakeholders: NITAG, ICC, TA providers
- Inform regional and global working groups on progress and bottlenecks
- Manage country specific dashboards on country readiness and implementation progress
- Ensure country preparedness to monitor data on PV, Surveillance, stocks monitoring,…
- Ensure readiness of AEFI surveillance system and communication
- Ensure training and development/adaptation of material provided

Country Readiness and Delivery workstream

Regionals working groups/task forces

Regions engaged in Global Coordination
THANK YOU